<scp>METTL3</scp>, an Independent Adverse Prognostic Factor for <scp>AML</scp>, Promotes the Development of <scp>AML</scp> by Modulating the <scp>PGC</scp>‐1α–<scp>MAPK</scp> Pathway and <scp>PGC</scp>‐1α–Antioxidant System Axis
The m<sup>6</sup>A methylation-modifying enzyme METTL3 is an independent prognostic factor for poor prognosis in AML patients. PGC-1α is a downstream signaling molecule of METTL3, and METTL3 affects its expression by regulating the m<sup>6</sup>A level of PGC-1α. PGC-1α acts as an oncogene in AML by affecting the MAPK pathway and antioxidant system.
Authors
- Yiwen Du (ORCID: https://orcid.org/0000-0002-6247-1786)
- Xiaoyu Wei (ORCID: https://orcid.org/0000-0003-4588-0155)
- Ya‐ling Tang (ORCID: https://orcid.org/0000-0002-2010-3571)
- Yuping Gong (ORCID: https://orcid.org/0000-0002-2437-9348)
- Xiaoyan Liu (ORCID: https://orcid.org/0000-0002-1732-5923)
- Ying Zhang (ORCID: https://orcid.org/0000-0001-8988-1649)
- Xiaojia Wang (ORCID: https://orcid.org/0000-0002-7005-0842)
- Ye Wu (ORCID: https://orcid.org/0000-0001-7040-4076)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/cam4.70771
- Citations
- 3
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Department of Science and Technology of Sichuan Province
- Key Research and Development Program of Sichuan Province